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SCF has been shown to synergize with G-CSF to mobilize
CD34þ PBPCs. In this study we report results from this
combination after a phase II trial of 32 patients with
malignant lymphoma randomized to receive recombinant
methionyl human SCF (ancestim, r-metHuSCF) in
combination with recombinant methionyl human G-CSF
(ﬁlgrastim, r-metHuG-CSF) (experimental arm A) or
routine chemotherapy plus ﬁlgrastim (conventional arm
B). The primary objective was to evaluate the side effects
and toxicity during priming and mobilization. The
secondary objectives were efﬁcacy by the level of blood-
circulating PBPCs, the number of harvest days and the
time to three-lineage engraftment after autografting.
First, during priming 5 patients had 8 serious events,
4 in each arm. A summary of all adverse events revealed
30 (94%) patients suffering from 132 events of all
grading. Second, neutropenia and thrombocytopenia was
documented in arm B. Third, 9/14 (64%) patients in arm
A reached the target of 5 million CD34þ cells/kg body
weight (bw) compared with 13/15 (87%) in arm B. The
results represent the ﬁrst randomized trial of growth
factor plus chemotherapy priming and indicate that a
formal phase III trial very unlikely may challenge
chemotherapy plus r-metHuG-CSF priming in candidates
for high-dose therapy.
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Introduction
Auto-SCT is used to support high-dose chemotherapy in
hematological malignancies.1–2 PBPCs have replaced BM
cells as the preferred source for transplantation because of
faster blood cell recovery.3–4 One variable of major effect
for post transplant care is the number of PBPCs
harvested.5–8 Therefore, several clinical studies have aimed
to identify priming regimens that improve progenitor and
stem cell mobilizations and collections without increased
toxicity. Frequently, ﬁlgrastim (recombinant methionyl
human G-CSF (r-metHuG-CSF)) is administrated alone;
however, ﬁlgrastim combined with chemotherapy has
proven more effective in the context of CD34þ cell
numbers harvested,9–11 and this combination is considered
the gold standard for priming and stem cell mobilization in
relapsed malignant lymphoma.
SCF is a glycoprotein growth factor that exerts an effect
on hematopoietic blood cell progenitors.12 Although SCF
alone exerts little colony-stimulating activity on normal
human BM cells in vitro, a combination of SCF with other
recombinant hematopoietic cytokines results in a synergis-
tic increase in the numbers of colonies.13 In vivo, the
addition of SCF to G-CSF (ﬁlgrastim) synergistically
increases PBPC mobilization compared with ﬁlgrastim
alone.14–17 Several clinical trials have reported the ability
of the combination of SCF with ﬁlgrastim to mobilize
PBPCs in patients with lymphoma, multiple myeloma,
breast and ovarian cancers even in heavily pretreated
patients.18–26
Priming using chemotherapy is toxic and costly,11 and
new priming procedures need to be established, which is the
background for this randomized pilot study. The hypoth-
esis is that elimination of chemotherapy from the priming
regimen may decrease the overall toxicity and the ability to
collect a sufﬁcient autograft, which, however, may be
circumvented by adding r-metHuSCF (ancestim) to the
priming regimen. The aim of this randomized phase II trial
was to evaluate the safety, toxicity and efﬁcacy of growth
factors in lymphoma patients who were considered
candidates for high-dose chemotherapy.
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Materials and methods
Patient eligibility
The study was reviewed and approved by the participating
institutional ethics committees (J. nr. H-KA-99040-GMS),
and all patients gave written informed consent before study
entry. The trial was performed before clinical trials had to
be registered at http://clinicaltrials.gov/ but has been
subsequently registered as NCT01016795. Patients were
eligible if they were candidates for high-dose chemotherapy
and auto-SCT, were between 18 and 65 years of age and
with histologically documented malignant lymphoma in
relapse, refractory or with PR to initial induction therapy.
Previous hematopoietic growth factor administration had
to be completed at least 1 week before study entry. Patients
were required to have an ANC ofX1.5 109/L, a plt count
of X100 109/L, serum creatinine o150mmol and bili-
rubin, aspartate aminotransferase, and alanine aminotrans-
ferase less than twice the upper limit deﬁned at the
investigating laboratory. In addition, patients had to have
an ECOG (Eastern Cooperative Oncology Group) perfor-
mance status 0, 1 or 2, and life expectancy of 46 months
with treatment.
Patients were excluded if they had received DexaBEAM
or miniBEAM27 therapy or previous high-dose chemother-
apy with autologous progenitor cell support. Because of the
possibility of systemic allergic-like reactions, patients with
severe allergic history (seasonal/recurrent asthma, anaphy-
lactic-type events, angioedema/recurrent urticaria and
allergy to insect venoms) were not included. Other
exclusion criteria included clinical and/or microbiological
signs of infection or fever, HIV seropositivity, known
allergy to Escherichia coli-derived products or signiﬁcant
nonmalignant disease. A history of asthma or other
signiﬁcant IgE-mediated hypersensitivities or required
concurrent use of b-adrenergic blocking agents was
prohibited because of potential interactions with the SCF
premedication.
Hematopoietic growth factors
Both ﬁlgrastim and SCF were supplied by Amgen Inc.
(Thousand Oaks, CA, USA). SCF was expressed in E. coli
as a 166 amino acid nonglycosylated protein and included
methionine at the N-terminus (r-metHuSCF); this was
provided as either an aqueous solution or a lyophilized
powder. Both the SCF and ﬁlgrastim were kept refrigerated
at 2–8 1C until the time of injection. Lyophilized SCF was
reconstituted with sterile water for injection before s.c.
administration.
Hematopoietic progenitor cell enumeration
All progenitor cell analyses were performed at an experi-
enced stem cell laboratory using standardized full-blood
CD34þ methodology.8,27–29 Samples were analyzed by ﬂow
cytometry on a FACScan (Becton Dickinson, Mountain
View, CA, USA) or a comparable cytometer after labelling
with phycoerythrin (PE)-conjugated anti-CD34 (HPCA-2;
Becton Dickinson) of a total of minimum 100 000 nucleated
CD45þ leukocytes. Cells stained with HPCA-2 were
identiﬁed by FL2 and low side scatter, and background
labelling was subtracted.
Central analysis of leukapheresis samples
Available leukapheresis samples were shipped to one
laboratory and analyzed by ﬂow cytometry to identify
and enumerate abnormal lymphocyte subsets, including B-
cell light-chain restriction.
Samples (N¼ 41) from 21 (66%) of the 32 patients were
analyzed on a four-color FACSCalibur (Becton-Dickinson)
with a six-tube panel of 14 pre-titrated monoclonal
antibodies directed against 12 Ags: CD56 FITC, CD33
PE, CD3 PerCP and APC, CD19 APC, CD45 FITC and
APC, CD34 PE, k and l light chains, CD20 PerCP, CD4
FITC, TCR gamma, dPE, and CD8 PerCP. Two tubes
contained unstained cells and IgG1 Ab controls for
unspeciﬁc staining, respectively.
The frozen samples were thawed in a 37 1C water bath
and washed once in a PBS solution containing DNAase
(100mL Buffer A, 0.5mL MgCl2 500mMþ 2.5mL
DNAase (Pulmozyme 1mg/mL)) to prevent clumping and
cell loss caused by sticky DNA fragments from dead cells,
and then washed once in buffer A (500mL PBS, 2.5 g
BSAþ 10mL Na-EDTA stock solution pH 5.5–5.7) and
adjusted to a cell concentration of 2 107 cells per mL.
Samples of 50mL were mixed with 50mL Ab solutions and
incubated for 30min at 4 1C, then washed twice in standard
buffer, resuspended to a volume of 3–400mL and analyzed im-
mediately. In each tube, 100 000 events (500 000 events in
the k–l tube) were acquired ungated and later analyzed
in CellQuestPro (BD Biosciences, San Jose, CA, USA) using
a FSC–SSC live gate, excluding debris and dead cells. Data
analysis was then repeated including dead cells as a control
measure. Reported data are on live gated cells. Calculations
were performed in Excel based on exported statistics ﬁles.
Study design
This was a randomized, open-label, multicenter study. It
consisted of a priming phase, a collection phase,
a transplantation phase and a 90-day follow-up. An overview
of the treatment of patients for this study is shown in
Figure 1. Enrolment was offered to all eligible patients
presenting at the participating institutions.
Priming phase. Patients were randomized in a 1:1 ratio to
either chemotherapy combined with 10mg/kg/day ﬁlgrastim
(control arm B), administered by s.c. injection for 14 days,
or the combination of 10 mg/kg/day ﬁlgrastim and SCF
administered s.c. at a dose of 20 mg/kg/day (experimental
arm A) for 8 days. Different injection sites were used for
each cytokine. The details of the cytokine dosing and
leukapheresis procedures for each treatment group are
shown in Figure 1.
The ﬁrst dose of SCF was administered on an in-patient
basis, with overnight observation after the injection.
Subsequent doses were administered on an outpatient basis
with at least 4 h of observation. All patients treated with
SCF received prophylaxis against mast cell-mediated
adverse effects. Prophylaxis consisted of 50mg diphenhy-
dramine orally every 6 h, 150mg ranitidine orally every
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12 h, two puffs of albuterol metered-dose inhaler and
120mg pseudoephedrine by sustained release. Administra-
tion of diphenhydramine and ranitidine began 12–24 h
before the ﬁrst dose of SCF and was timed so that a dose of
all four medications was delivered approximately 1 h before
each injection of SCF. Diphenhydramine and ranitidine
therapy was continued until 48 h after the last SCF
injection.
Collection phase. Leukaphereses were performed using a
Baxter Fenwall CS3000 (Baxter, Deerﬁeld, IL, USA), a
Cobe Spectra (COBE Laboratories, Lakewood, CO, USA)
or a comparable machine. A blood volume of approxi-
mately 10L was processed at each daily leukapheresis.
Patients were scheduled to undergo leukapheresis on the
day when the CD34þ cell blood level reached X20/uL.
The required minimum cumulative yield of CD34þ cells
was 5.0 106 cells/kg actual body weight (bw), which
represented an acceptable standard in the literature at the
time this trial was initiated. If this minimum yield was not
achieved after a total of at least 4 leukapheresis, the patient
was classiﬁed as a mobilization failure (poor mobilizers)
and was managed with either further leukapheresis
or supplementation of the PBPCs with harvested BM for
progenitor cell support. The leukapheresis product
collected on each day was processed and cryopreserved.
Patients with o5 106 CD34þ cells/kg harvested
proceeded to treatment phase at the discretion of the
investigator. No assessment of CD34þ cell subsets or
malignant clone cells was performed on the leukapheresis
product before storage.
Transplantation and follow-up phase. Within 6 weeks of
completing the leukapheresis procedure, patients were
admitted to hospital and treated with myeloablative
therapy (BEAM) followed by autologous PBPC transplan-
tation at day 0. BEAM conditioning therapy consists of
BCNU 300mg/m2 i.v. (30min) q.d. on day –7, etoposide
Inclusion
Patients with relapsed Hodgkin’s disease or relapsed
low-grade or high-grade NHL, age 18 – 65 years,
written informed consent 
Leukapheresis*
Performed with a blood level > 20 /μl 
and harvest up to 5 x 106 CD34+ cells/kg
** PBPC re-infusion   Day 0
Filgrastim 5 μg/ kg - Day +3
until ANC recovery***
Leukapheresis will start when CD34+ count in peripheral blood ≥ 20/μl and will be performed daily until an
optimal yield of 5 x 106 CD34+ cells/kg is achieved (see section 6.2 for details) or until 5 apheresis are
performed. 
The total yield of CD34+ cells to be transfused will be 5 x106 CD34+ cells/kg
Leukocyte count >1 x 109/l each day for three days or > 10 x 109/l for one day.
Priming arm B (conventional)
Day 0: cyclophosphamide 2-4 g/m2
or local regimen (e.g. MIME)
Day 1: Filgrastim 10μg/kg/day until 
leukaphereses have been completed
Priming arm A (experimental)
Day 1: rh-SCF 20 μg/kg +
Filgrastim 10 μg/kguntil
leukaphereses have been
completed
Transplantation
BEAM Day -7 to  -3
End
Salvage therapy
In accordance with local experiences.
patients receiving dexaBEAM or miniBEAM will be 
excluded as well as previously transplanted patients 
Randomization
**
***
*
Figure 1 Study design and treatment ﬂow charts.
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200mg/m2 i.v. (30min) q.d. on days –7 to –4, Ara-C
200mg/m2 i.v. (30min) b.i.d. on days minus –7 to –4 and
melphalan 140mg/m2 i.v. (5min) q.d. on day –3. After 2
days of rest, the total number of 5 106 CD34þ /kg PBPCs
were reinfused on day 0.
Beginning on day 0 of transplantation, ﬁlgrastim was
administered at a dose of 5 mg/kg/day from day 3 until
ANC recovery (ANC X1.0 109/L for 3 consecutive days
or X10 109/L for 1 day) or for a maximum of 28 days
(whichever occurs ﬁrst). Antibiotics, blood products, and
i.v. ﬂuids were administered as clinically indicated.
Complete blood counts were obtained daily until ANC
was X1.0 109/L and the plt level was X20 109/L and
were obtained three times per week thereafter until the plt
count was X50 109/L on two determinations separated
by a minimum of 48 h. Patients were assessed daily during
hospitalization and weekly after discharge until plt recovery
had occurred.
Throughout the study, investigators were allowed to
prescribe any concomitant medications or treatments
deemed necessary to provide adequate supportive care
(except additional cytokines, IFN, WBC transfusions,
other investigational agents or b-adrenergic blocking
agents). Concomitant medications prescribed for serious
adverse events and disallowed concomitant medications
were recorded on the case record form. Administration of
chemotherapy (other than as speciﬁcally deﬁned in the
protocol) was not allowed while the subject was on study
(that is, once enrolled, until the end of study).
Plt transfusions were given to maintain a plt count of
410 109/L, and transfusion dates were recorded. A plt
transfusion comprised either a deﬁned number of units of
random donor plts or a single-donor pack, depending on
the practice of the site. If the subject was febrile or suffered
from hemorrhage, plts could be given at the discretion of
the investigator, and all dates were then recorded. An
investigator comment on the case record form was required
for all plt transfusions given when plt count was410 109/L.
All patients were discharged from the hospital when the
ANC was X1.0 109/L and i.v. antibiotic therapy was no
longer necessary. Subjects underwent an end of treatment
phase evaluation at 30 days after receiving the last dose of
ﬁlgrastim or when their plt count exceeded 50 109/L,
whichever occurred ﬁrst, after late intensiﬁcation therapy.
At the end visit, a physical examination, including ECOG
status, engraftment and disease status, was performed.
Adverse events were recorded in each phase of the study.
Special attention was paid to any allergic-type reactions.
The relationship to the investigational drug was scored.
Objectives, clinical end point, sample sizes and data analysis
The clinical objective of this randomized phase II trial was
to compare the safety and toxicity (primary), as well as
efﬁcacy (secondary), of a growth factor ‘only’ priming by
r-metHuSCF plus ﬁlgrastim (arm A) with that of chemo-
therapy plus ﬁlgrastim priming (arm B).
Primary end points. Safety and toxicity were assessed by
morbidity, including unexpected adverse events associated
with the priming and the transplantation phases occurring
during the study, and measured and graded by CTC
(common toxicity criteria). Other assessments included
days with neutropenia and thrombocytopenia, days with
fever on antibiotics, days in hospital and numbers of
transfusions.
Secondary end points. Efﬁcacy was assessed by graft-
related variables during the mobilization, collection and
follow-up phase. These included the blood level of CD34þ
cells from day 3 to the end of priming and harvest, total
number of CD34þ cells harvested per day of leukapheresis
and time to three-lineage engraftment by a ﬁxed autograft-
ing of 5.0 106 cells/kg bw.
Sample size considerations. Sample size considerations
were based on feasibility and estimates from published
toxicity data,14–26 as well as a retrospective toxicity
evaluation of a standard chemotherapy-based priming
procedure.11 A sample size of 60 was chosen to gain as
much information as possible about the response variables
deﬁned. The study was closed by Amgen after inclusion of
32 patients, which however was considered sufﬁcient by the
investigators to evaluate the trial end points.
Statistical analysis. All subjects who were randomized
and had growth factor administered during the priming
phase of the trial were analyzed on intent to treat.
Statistical analysis was used to determine whether there
were any signiﬁcant differences between the groups with
respect to the described end points above. An exact
binomial test was used to test for equality of proportions
between the two treatment arms.
Results
Study population
Demographic-, disease- and therapy-related data from the
32 subjects who were randomized and entered into the
study, with 16 patients in each arm, is given in Table 1. Of
these, 29 (91%) patients entered the collection phase, and
25 (78%) reached the target of 5 million CD34þ cells/kg. A
total number of 21 (67%) patients completed the trans-
plantation phase before study closure.
Safety evaluation summarized by adverse events
During the mobilization phase we identiﬁed ﬁve patients
with eight serious events, four in each arm. Two patients
(13%) in arm A suffered from one allergic, two febrile and
one rigor episode. Three patients (19%) in arm B suffered
from two febrile and one hematological episodes of severe
grading (Table 2). Evaluation during the transplantation
phase identiﬁed three patients with four serious events, one
hepatic failure in arm A and central nervous system
affection, seizure and skin erythema in arm B (results not
shown).
A summary of all adverse events revealed 30 (94%)
patients suffering from 132 events of all grading reported in
accordance with the CTC criteria. As expected, 10 patients
(63%) reported erythema, pigmentation or reaction from
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the injection site in arm A, which was not observed in arm
B. On the contrary 9 (56%) from arm B had fever,
compared with only 3 (19%) from arm A. A detailed
analysis review of data revealed no differences when the
two arms were compared for adverse events from central or
peripheral nervous system (dizziness, headache and sei-
zure), gastrointestinal tract (diarrhea, nausea, pain and
vomiting), heart (rate and rhythm), hematopoietic system
(penia and hemorrhage), liver, musculoskeletal, urinary or
respiratory systems and the skin (data not shown).
Toxicity evaluation
In arm B, neutropenia and thrombocytopenia were
documented in 14 (88%; median 4 days, range 0–10) and
in 3 (19%; median 0 days, range 0–6) patients, respectively.
In comparison, no cytopenia was documented in arm A.
Fever occurred in 8 (50%) patients from arm B, and in only
1 (6%) patient from arm A. Transfusions were admini-
stered 12 times in arm B, but never in arm A.
Efﬁcacy evaluation
The mobilization of CD34þ cells reached a maximum on
day 5 of 30 CD34þ /mikrol (median, range 5–162) in arm A
compared with a maximum on day 10 of 124/mikrol
(median, range 2–206) in arm B.
The median (range) number of CD34þ  106 cells/kg
harvested was 5.4 (1.9–8.5) in arm A and 8.3 (1.4–16.1) in
arm B. Only 1/14 (7%) patient in arm A compared with 10/
15 (67%) patients in arm B reached the target of 5 106
CD34þ /kg on the ﬁrst day of leukapheresis (P¼ 0.00018).
The number of leukaphereses required to achieve the target
of 5.0 million CD34þ cells/kg varied from 1 to 5 days. In
arm A 9/14 (56%) patients reached the target when
compared with 13/15 (81%) patients in arm B (P¼ 0.24;
Table 3).
Post transplant, after reinfusion of the exact number of 5
million CD34þ cells/kg bw, there was no difference
between the two groups in terms of the number of days
in hospital, number of days on antibiotics, number of
transfusions (results not given) or number of serious
adverse events by CTC criteria (results not given). Of
special interest, the time to reticulocyte, plt and netrophi-
locyte recoveries were median (range) 12 days (10–14), 11
days (8–16) and 11 days (10–12) in arm A, and 12 days
(9–16), 11 days (8–16) and 10 days (9–13) in arm B,
respectively.
Graft evaluation
Enumeration of selected subsets of interest in the harvested
leukapheresis products was performed by ﬂow cytometry,
and it conﬁrmed the higher level of CD34þ cells harvested
in arm B compared with arm A (Table 4). However, no
difference in B- and T-cell levels were identiﬁed and no
differences in the level of potential clonal cells were found
(Table 5).
Discussion
In this randomized pilot study the addition of r-metHuSCF
(ancestim) to ﬁlgrastim was compared with conventional
Table 2 Serious adverse events during mobilization phase
Variable Arm A:
r-metHuSCF+
ﬁlgrastim
mobilization number
Arm B:
chemotherapy+ﬁlgrastim
mobilization number
Number of patients 16 16
Total number of events: 4 4
Allergic reactions 1 0
Fever 2 2
Rigors 1 0
Hematological 0 1
Respiratory 0 1
Abbreviation: r-metHuSCF¼ recombinant methionyl human SCF.
Table 3 Number of leukapheresis to achieve 5 million CD34+
cells/kg
Variable Arm A:
r-metHuSCF+
ﬁlgrastim
mobilization
number
Arm B:
chemotherapy+
ﬁlgrastim
mobilization
number
Number of patients 16 16
Number of daily leukapheresis 1/2/
3/4/5/45
1/7/0/0/1/5 10/2/0/0/1/2
Leukapheresis not triggered 2 1
Abbreviation: r-metHuSCF¼ recombinant methionyl human SCF.
Table 1 Demographic, disease and therapy characteristics at the time of inclusion
Variable Arm A: r-metHuSCF+ﬁlgrastim
mobilization number (%)
Arm B: chemotherapy+ﬁlgrastim
mobilization number (%)
Gender male/female 13 (81%)/3 (19%) 8 (50%)/8 (50%)
Age years median (range) 50 (20–68) 50 (23–63)
ECOG performance scale 0/1 11 (69%)/4 (25%) 11 (69%)/4 (25%)
Disease MHdg/NHL low/high grade 3 (19%)/4 (25%)/9 (56%) 4 (25%)/1 (6%)/11 (69%)
Marrow involvement +/ 2 (13%)/11 (69%) 4 (25%)/11 (69%)
Disease status
Prim Refract/PR/relapse
0 (0%)/4 (25%)/10 (63%) 3 (19%)/4 (25%)/7 (44%)
Previous radiotherapy 3 (19%) 4 (25%)
Ann Arbor staging I–II/III/IV 6 (38%)/3 (19%)/7 (44%) 3 (19%)/5 (31%)/8 (50%)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; NHL¼ non-Hodgkin’s lymphoma; r-metHuSCF¼ recombinant methionyl human SCF.
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chemotherapy plus ﬁlgrastim priming. It was the study
hypothesis that removing chemotherapy and adding rhSCF
to the priming scheme would allow a sufﬁcient PBPC
harvest in most patients safely and with reduced toxicity
and side effects. The clinical trial was designed to generate
data on safety, toxicity and efﬁcacy during the experimental
nonchemotherapy-based priming regimen (arm A) and
compare with a conventional chemotherapy-based strategy
(arm B) in relapsed or refractory lymphoma patients who
were considered candidates for high-dose therapy.
Our study shows that removal of chemotherapy from the
mobilization regimen will reduce toxicity. However, the
drawback is a reduced ability to harvest adequate CD34þ
cell numbers.
Administration of the experimental combination of SCF
and G-CSF was safe and well tolerated with a low risk of
adverse events consistent with previous observations.14–26
No serious allergic-like reactions were observed and the
absence of such events in the present study might be related
to the careful screening for allergy history, systematic
premedication or relatively small patient numbers for
detecting low-frequency events. In other large randomized
studies, such severe events were reported in 3–10% of
patients.18,25
The efﬁcacy of the priming regimens was compared by
the number of leukapheresis required to achieve a target of
5 million CD34þ cells/kg bw, which varied from 1 to 5
days. In the experimental arm, 9/14 (56%) patients reached
the target, compared with 13/15 (81%) in the conventional
arm. This result supported the observation that the
maximum blood level and harvest of CD34þ cells in the
chemotherapy arm was increased 5–6 and 1.5 times,
respectively (data not shown). Finally, only 1 (6%) patient
compared with 10 (63%) patients in arm B reached the
target of 5 million CD34þ cells/kg bw on the ﬁrst day of
leukapheresis. These results are not in line with those
observed in other trials of the combination of SCF and
G-CSF to improve PBPC collection.18–26,30–33 The explana-
tion might be that the present experimental arm was
compared with standard chemotherapy plus G-CSF and
included patients with malignant lymphoma, most of whom
were heavily pre-treated before relapse or disease progres-
sion and even included patients with primary refractory
disease.
In summary, a whole spectrum of priming studies has
evaluated the effect of SCF on the grade of mobilization.
However, one missing link in the literature is the present
comparison between experimental combined growth
factors and conventional chemotherapy priming. The
present pilot study is the ﬁrst to evaluate this comparison
and conclude that a phase III trial is unlikely to change the
present recommendation for malignant lymphoma patients
Table 4 Leukocyte subsets in leukapheresis samples analyzed by ﬂow cytometry
Treatment group % CD34+ % CD33+ % CD19+ % CD56+ CD3 % CD3+ % CD4+ CD3+ % CD8+ CD3+ % TCR+
CD8+ CD3+
Arm A (N¼ 10) r-metHuSCF and ﬁlgrastim mobilization
Mean 1.4 65.0 5.7 12.3 23.2 7.2 17.5 2.8
Median 0.7 65.6 0.5 10.6 21.8 6.8 17.8 2.3
Min 0.1 46.5 0.0 2.4 11.5 1.8 7.1 0.2
Max 4.4 84.4 33.5 25.2 48.7 18.9 28.0 8.2
N 10 10 10 10 10 10 10 10
Arm B (N¼ 11) chemotherapy and ﬁlgrastim mobilization
Mean 3.1 69.5 3.6 9.3 21.2 8.4 13.8 1.5
Median 2.5 77.4 0.8 9.8 14.1 6.4 8.2 0.7
Min 0.3 37.9 0.0 3.5 3.2 1.8 2.0 0.1
Max 8.2 95.6 27.0 13.8 46.4 22.2 26.9 4.0
N 11 11 11 11 11 11 11 11
Abbreviation: r-metHuSCF¼ recombinant methionyl human SCF.
Table 5 Normal and clonal B cells in leukapheresis samples analyzed by ﬂow cytometry
Treatment group Diagnosis Patients Clonal B
cells
Live gate
events *105
% CD19+
in live gate
o100 CD19+
events
% CD19+
o1
% CD19+
1–10
% CD19+ 410
N N Mean Mean N N Mean N Mean N Mean
Arm A (N¼ 10) r-metHuSCF
and ﬁlgrastim mobilization
B-NHL 5 0 2.8 6.9 3 4 0.0 0 1 34.1
HD 2 0 2.2 10.2 0 0 1 4.9 1 15.6
T-NHL 3 0 2.3 1.8 0 2 0.4 1 4.6 0
Arm B (N¼ 11) chemotherapy
and ﬁlgrastim mobilization
B-NHL 7 2 1.7 5.2 1 3 0.3 3 2.7 1 27.6
HD 2 0 2.0 0.5 0 2 0.5 0 0
T-NHL 2 0 1.9 1.1 0 1 0.1 1 2.0 0
Abbreviations: B-NHL¼B-cell non-Hodgkin’s lymphoma; HD¼Hodgkin’s disease; r-metHuSCF¼ recombinant methionyl human SCF; T-NHL¼T-cell
non-Hodgkin’s lymphoma.
SCF priming in malignant lymphoma
HE Johnsen et al
49
Bone Marrow Transplantation
considered candidates for high-dose therapy that conven-
tional chemotherapy plus G-CSF is the most effective
priming regimen with an acceptable toxicity and safety
proﬁle.
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